This Article Full Text Full Text (PDF) All Versions of this Article: 51/2/326    most recent HYPERTENSIONAHA.107.101188v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zoccali, C. Articles by Malatino, L. Search for Related Content PubMed PubMed Citation Articles by Zoccali, C. Articles by Malatino, L. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Compound via MeSH Substance via MeSH Hazardous Substances DB (L)-ARGININE NITRIC OXIDE Medline Plus Health Information Cardiomyopathy Related Collections Hypertrophy Myocardial cardiomyopathy disease Clinical Studies

(Hypertension. 2008;51:326.)
© 2008 American Heart Association, Inc.

Original Articles

Urotensin II and Cardiomyopathy in End-Stage Renal Disease

Carmine Zoccali; Francesca Mallamaci; Frank Antonio Benedetto; Giovanni Tripepi; Patrizia Pizzini; Sebastiano Cutrupi; Lorenzo Malatino

From the Consiglio Nationale delle Ricerche (CNR)-Istituto di Biomedicina (IBIM) (C.Z., F.M., F.A.B., G.T., P.P., S.C.), Institute of Biomedicine, Clinical Epidemiology and Pathophysiology of Renal Diseases and Hypertension and Division of Nephrology, Dialysis and Transplantation, Reggio Calabria, Italy; and the Department of Medicine (L.M.), University of Catania, Catania, Italy.

Correspondence to Carmine Zoccali, Unità Operativa di Nefrologia (VI Piano) e CNR, Ospedali Riuniti, 89124 Reggio Calabria, Italy. E-mail carmine.zoccali{at}tin.it

Circulating urotensin (UTN) is increased in patients with heart failure and in patients with renal diseases, and UTN antagonism is currently considered as a potential treatment for these conditions. Contrary to this contention, studies in end-stage renal disease suggest that, perhaps because of interference with sympathetic and NO systems, UTN may be cardioprotective. Therefore, we investigated the relationship between circulating UTN and echocardiographic parameters of left ventricular function (midwall fractional shortening), left atrial volume, and myocardial geometry (mean wall thickness and relative wall thickness) in 191 patients with end-stage renal disease. UTN was associated directly (r=0.39; P<0.001) with left ventricular systolic function and inversely with left atrial volume (r=–0.40; P<0.001) and the muscular component of the left ventricular (UTN versus mean wall thickness: r=–0.30, P<0.001; UTN versus relative wall thickness: r=–0.32, P<0.001). Adjustment for a series of 11 risk factors produced a relatively small change in the strength of these relationships. However, further adjustment for plasma norepinephrine or, particularly so, for the endogenous inhibitor of NO synthase asymmetrical dimethyl arginine produced a 33% to 50% decrease in the strength of such associations. Of note, there was a strong UTN-asymmetrical dimethyl arginine interaction in determining midwall fractional shortening (P=0.001) and mean wall thickness (P=0.006). These data support the hypothesis that high UTN is cardioprotective in end-stage renal disease and that interference by UTN with sympathetic activity and NO synthesis represents an intermediate mechanism mediating the favorable echocardiographic profile of patients with high UTN. Additional mechanistic insights may be needed before launching long-term clinical trials with UTN antagonists in patients with end-stage renal disease.

Key Words: asymmetrical dimethyl arginine • cardiomyopathy • cardiovascular risk • end stage renal disease • sympathetic activity • urotensin II

This article has been cited by other articles:

				Y.-H. Chen, T. G. Yandle, A. M. Richards, and S. C. Palmer Urotensin II Immunoreactivity in the Human Circulation: Evidence for Widespread Tissue Release Clin. Chem., November 1, 2009; 55(11): 2040 - 2048. [Abstract] [Full Text] [PDF]